期刊
LANCET HAEMATOLOGY
卷 8, 期 3, 页码 E185-E193出版社
ELSEVIER SCI LTD
DOI: 10.1016/S2352-3026(20)30429-4
关键词
-
类别
资金
- NCI [U24CA076518]
- National Heart, Lung and Blood Institute (NHLBI)
- National Institute of Allergy and Infectious Diseases
- NHLBI [U24HL138660, OT3HL147741, U01HL128568]
- NCI
- Health Resources and Services Administration (HRSA) [HHSH250201700006C, HHSH250201700007C]
- Office of Naval Research [N00014-18-1-2850, N00014-18-1-2888, N00014-20-1-2705]
- NIH [P01CA111412, R01CA152108, R01CA215134, R01CA218285, R01CA231141, R01AI128775, R01HL126589, R01HL129472, R01HL130388, R01HL131731, U01AI069197, U01AI126612]
- Be the Match Foundation
- Boston Children's Hospital
- Dana Farber
- St Baldrick's Foundation
- Stanford University
- Medical College of Wisconsin the National Marrow Donor Program
- AbbVie
- Actinium Pharmaceuticals
- Adaptive Biotechnologies
- Adienne SA
- Allovir
- Amgen
- Angiocrine Bioscience
- Astellas Pharma US
- AstraZeneca
- Atara Biotherapeutics
- Bluebird bio
- Bristol Myers Squibb
- Celgene
- CSL Behring
- CytoSen Therapeutics
- Daiichi Sankyo
- Gamida-Cell
- Genentech
- HistoGenetics
- Incyte Corporation
- Janssen Biotech
- Jazz Pharmaceuticals
- Johnson Johnson
- Kiadis Pharma
- Kite (a Gilead Company)
- Kyowa Kirin
- Legend Biotech
- Magenta Therapeutics
- Mallinckrodt
- Merck Company
- Merck Sharp Dohme
- Millennium
- Takeda Oncology
- Miltenyi Biotec
- Novartis
- Omeros
- Oncoimmune
- Orca Biosystems
- Pfizer
- Pharmacyclics
- Sanofi Genzyme
- Shire
- Sobi
- Stemcyte
- Takeda
- Terumo
- Viracor Eurofins
- Vor Bio Pharma
- Xenikos
This study examined the characteristics and outcomes of HSCT recipients after developing COVID-19. It found that recipients of autologous and allogeneic HSCT who develop COVID-19 have poor overall survival rates. Factors such as age, sex, and time since transplantation were associated with higher risk of mortality in HSCT recipients.
Background Haematopoietic stem-cell transplantation (HSCT) recipients are considered at high risk of poor outcomes after COVID-19 on the basis of their immunosuppressed status, but data from large studies in HSCT recipients are lacking. This study describes the characteristics and outcomes of HSCT recipients after developing COVID-19. Methods In response to the pandemic, the Center for International Blood and Marrow Transplant Research (CIBMTR) implemented a special form for COVID-19-related data capture on March 27, 2020. All patients-irrespective of age, diagnosis, donor type, graft source, or conditioning regimens-were included in the analysis with data cutoff of Aug 12, 2020. The main outcome was overall survival 30 days after a COVID-19 diagnosis. Overall survival probabilities were calculated using Kaplan-Meier estimator. Factors associated with mortality after COVID-19 diagnosis were examined using Cox proportional hazard models. Findings 318 HSCT recipients diagnosed with COVID-19 were reported to the CIBMTR. The median time from HSCT to COVID-19 diagnosis was 17 months (IQR 8-46) for allogeneic HSCT recipients and 23 months (8-51) for autologous HSCT recipients. The median follow-up of survivors was 21 days (IQR 8-41) for allogeneic HSCT recipients and 25 days (12-35) for autologous HSCT recipients. 34 (18%) of 184 allogeneic HSCT recipients were receiving immunosuppression within 6 months of COVID-19 diagnosis. Disease severity was mild in 155 (49%) of 318 patients, while severe disease requiring mechanical ventilation occurred in 45 (14%) of 318 patients-ie, 28 (15%) of 184 allogeneic HSCT recipients and 17 (13%) of 134 autologous HSCT recipients. At 30 days after the diagnosis of COVID-19, overall survival was 68% (95% CI 58-77) for recipients of allogeneic HSCT and 67% (55-78) for recipients of autologous HSCT. Age 50 years or older (hazard ratio 2.53, 95% CI 1.16-5.52; p=0.020); male sex (3.53; 1.44-8.67; p=0.006), and development of COVID-19 within 12 months of transplantation (2.67, 1.33-5.36; p=0.005) were associated with a higher risk of mortality among allogeneic HSCT recipients, and a disease indication of lymphoma was associated with a higher risk of mortality compared with plasma cell disorder or myeloma (2.41, [1.08-5.38]; p=0.033) in autologous HSCT recipients. Interpretation Recipients of autologous and allogeneic HSCT who develop COVID-19 have poor overall survival. These data emphasise the need for stringent surveillance and aggressive treatment measures in HSCT recipients who develop COVID-19. Copyright (C) 2021 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据